Rare Blood Disease Drug Wins FDA ApprovalAggressive Systemic Mastocytosis, Approvals, FDA, Hematologic Diseases, New Indications, Overall Survival (OS), TherapeuticsThe U.S. Food and Drug Administration approved Blueprint Medicines’ Ayvakit (avapritinib) for the treatment of adult patients with advanced systemic mastocytosis. Read more June 17, 2021/by Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2021/06/Rare-Blood-Disease-Drug-Win-Marks-Fourth-Approval-for-Blueprint-Medicines-BioSpace-6-17-21.jpeg 350 625 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2021-06-17 12:17:532021-06-17 12:49:46Rare Blood Disease Drug Wins FDA Approval